Table 4

Diagnostic procedures and related complications for subsolid nodules detected at baseline and follow-up screening

Total (n=293)Baseline subsolid nodule (n=266)New subsolid nodule (n=27)P value*
Time of biopsy, n (%)0.793
 At first detection49 (16.7)44 (16.5)5 (18.5)
 After follow-up244 (83.3)222 (83.5)22 (81.5)
Time from first detection to biopsy (months), mean±SD29.8±39.430.1±39.726.7±37.10.651
Type of initial biopsy for diagnosis, n (%)0.267
 Video-assisted thoracic surgery258 (88.1)236 (88.7)22 (81.5)
 Percutaneous needle biopsy30 (10.2)25 (9.4)5 (18.5)
 Bronchoscopy-guided biopsy5 (1.7)5 (1.9)0 (0)
Range of surgical resection, n/N (%)†0.249
 Lobectomy146/276 (52.9)136/252 (54.0)10/24 (41.7)
 Segmentectomy or wedge resection130/276 (47.1)116/252 (46.0)14/24 (58.3)
Required rebiopsy for insufficient diagnosis, n (%)2 (0.7)2 (0.8)0 (0)1.000
Complications related to invasive biopsy, n (%)
 Pneumothorax requiring pleurodesis23 (7.8)22 (8.3)1 (3.7)
 Postoperative pneumonia3 (1.0)3 (1.1)0 (0)
 Bleeding requiring additional intervention2 (0.7)2 (0.8)0 (0)
 Pulmonary thromboembolism1 (0.3)1 (0.4)0 (0)
 Vocal cord palsy1 0.3)1 (0.4)0 (0)
 Chylothorax7 (2.4)7 (2.6)0 (0)
 Bronchial stenosis1 (0.3)1 (0.4)0 (0)
 Persistent pleural effusion5 (1.7)5 (1.9)0 (0)
 Acute coronary syndrome or stroke1 (0.3)0 (0)1 (3.7)
Diagnosed as lung cancer, n (%)227 (77.5)210 (78.9)17 (63.0)0.058
Diagnosed as benign (false-positive), n (%)65 (22.2)55 (20.7)10 (37.0)0.051
Pathological diagnosis of benign nodule, n/N (%)0.009
 AAH34/65 (52.3)32/55 (58.2)2/10 (20.0)
 Focal fibrosis9/65 (13.8)9/55 (16.4)0/10 (0)
 Inflammatory nodule‡17/65 (26.2)11/55 (20.0)6/10 (60.0)
 Other benign condition§5/65 (7.7)3/55 (5.5)2/10 (20.0)
  • *The p value is based on the comparison between baseline and new nodules.

  • †All nodules resected for diagnosis or treatment underwent video-assisted thoracic surgery with the exception of one case that converted to open thoracotomy during video-assisted thoracic surgery due to uncontrolled bleeding.

  • ‡Including chronic inflammation and infectious nodules.

  • §Including nodules related with cryptogenic organising pneumonia, vasculitis, IgG4 disease and placental transmogrification.

  • AAH, atypical adenomatous hyperplasia.